NEWS

WIRES

OTHER

Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16

    Date:      Tuesday, March 16, 2010
    Time:      10:30 AM PST (Track 3)
    Location:  The Ritz Carlton, Laguna Niguel
    Presenter: Mr. Allen Tang, Assistant to the Chairman and CEO

Conference participation is by invitation only and registration is mandatory. For more information on the conference, or to book a one-on-one with the Company, contact your ROTH representative or visit http://www.roth.com .

About Roth Capital Partners, LLC

Founded in 1984, ROTH Capital Partners is a full service investment banking firm dedicated to the small-cap public market. The firm has raised over $12.6 billion for public companies and completed approximately 160 merger, acquisition and advisory assignments. ROTH has participated in underwriting IPOs for small-cap companies, has helped develop the PIPE financing structure, and more recently in underwriting offerings from shelf registration statements. ROTH was one of the first U.S. investment banks to focus on financing small-cap Chinese companies, and established a Representative Office in Shanghai in 2007.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") inChina. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 23 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughoutChina with a sales force of 720 salespeople. Tianyin is headquartered inChengdu,Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release or upcoming conference are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO
     Tel: +86-158-2122-5642
     Email: Allen.y.tang@gmail.com

    Investors:
     Mr. Matthew Hayden, HC International
     Tel: +1-561-245-5155
     Email: matt.hayden@hcinternational.net
     Web: http://www.hcinternational.net

SOURCE Tianyin Pharmaceutical Co., Inc.